Multi-pathway blood biomarkers to target and monitor multidimensional prevention of cognitive and functional decline (nested in the IN-TeMPO study framed within the world-wide FINGERS network)

Publication date: 7 Mag 2025

JournalSource: OPENALEXOpenAlex type: articleOpen Access
Authors: Gessica Sala, Luca Cuffaro, Federico Emanuele Pozzi, Simona Andreoni, Chiara Bazzini, Elisa Conti, C Zoia, Simone Beretta, Lucio Tremolizzo, Giuseppe Bellelli, Chukwuma Okoye, María Cristina Ferrara, Annamaria De Luca, Roberta Lenti, Paola Mantuano, Paola Pontrelli, Alessandra Stasi, Giovanni Defazio, Vincenzo Solfrizzi, Lucilla Crudele, Cristina Airoldi, Ferdinando Chiaradonna, Maria Pia Longhese, Giovanni Messina, Antonino Natalello, Ivan Orlandi, Alessandra Aloisi, Simonetta Capone, Assunta Ingannato, Benedetta Nacmias, Daniela Capello, Francesca Mangialasche, Carlo Ferrarese

Background: As the population ages, the identification of preventive strategies able to delay cognitive and functional decline associated with aging represents a major challenge. To date, multidimensional approaches seem to be effective in reducing or delaying the onset of age-related diseases. Objectives: The multicentric randomized controlled trial IN-TeMPO (ItaliaN study with Tailored Multidomain interventions to Prevent functional and cognitive decline in community-dwelling Older adults, ClinicalTrials.gov ID NCT06248723), framed within the World-Wide FINGERS network, aims to verify the efficacy of guided multidomain interventions in preventing age-related cognitive and functional decline. Within this study, we will explore a comprehensive array of established and exploratory blood biomarkers of several pathologic age-related processes, including Alzheimer's disease (AD), neurodegeneration, inflammation, senescence and sarcopenia, to stratify subject risk and assess the effect of multidomain interventions on biomarkers. Design and participants: = 1,662) both at the baseline and at the end of the study (12 months). Exploratory additional biomarkers will be measured at the same time points in a subgroup of 100 subjects: BDNF, ghrelin, IGF-1, irisin and redox status in plasma as markers of sarcopenia/senescence and oxidative stress, gamma-H2AX in PBMCs as marker of senescence, and amyloid beta aggregates in plasma, urine and erythrocytes as supportive markers of AD. Untargeted metabolomics analysis in plasma and untargeted volatilomics analysis in whole blood and urine will be performed to explore molecular alterations that may be associated with the pathogenesis and progression of age-related diseases in frail older adults with the aim of identifying novel potential biomarkers. Conclusion: The comprehensive clinical use of multiple laboratory biomarkers can contribute both to the early identification of trajectories of cognitive and functional decline in older adults, and to the identification of mechanisms underlying the effect of multidisciplinary interventions on age-related pathological processes.

Origin
Frontiers in Aging Neuroscience
Volume
17
Pages
1581892
Cited by
5